Clinical trials: Post Menopausal Breast Cancer, active
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
High Risk for Invasive Breast Cancer
SHORTened Duration of TAMoxifen
The purpose of this study is to learn whether a shorter-duration, low-dose tamoxifen regimen can reduce the risk of developing breast cancer or breast cancer recurrence in post-menopausal women who are at increased risk for…
- Trial name
- NCT07806630
- Testing
- Tamoxifen, Tamoxifen (Nolvadex)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Rutgers, The State University of New Jersey
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.
The goal of this clinical trial is to learn whether letrozole, a hormone therapy drug, is effective in treating early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to nearby lymph nodes in…
- Trial name
- NELOPHER (NCT07394946)
- Testing
- Letrozole
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Cancer Care Hospital & Research Centre Foundation, Lahore
Breast Cancer
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer
Breast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocrine therapy the optimal timing for their has not been clearly defined yet.
- Trial name
- GIM10-CONSENT (NCT02918084)
- Testing
- Anastrozole or Letrozole or Exemestane
- Where
- 74 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab.
- Trial name
- NCT05590949
- Testing
- Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced ER-Positive HER2-Negative Breast Cancer
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.
- Trial name
- SERENA-2 (NCT04214288)
- Testing
- AZD9833, Fulvestrant
- Where
- 85 sites in United States, Belgium and 14 more
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Breast Cancer Female, Cardiometabolic Syndrome
Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study
POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of…
- Conditions
- Breast Cancer Female, Cardiometabolic Syndrome, Metabolism Disorder, Lipid, Autonomic Dysfunction
- Trial name
- POWER Health (NCT06336070)
- Testing
- HIIT program (8 weeks), MPI program (8 weeks)
- Where
- Spain
- Volunteers
- 56 people
- Sponsor
- University of Valencia
Early Stage Breast Cancer
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
This study will compare the effects on cardiorespiratory fitness (CRF) of aerobic exercise in different amounts (number of minutes/session) over different periods of time (number of weeks).
- Trial name
- NCT04458532
- Testing
- Aerobic Training
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Risk Reduction, Breast Cancer
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms (hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6 months versus a wait list control.
- Trial name
- NCT04821141
- Testing
- Bazedoxifene and Conjugated Estrogens
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Breast Cancer
Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer
The primary endpoint of this study is to determine whether cycles of short term FMD exposure to a fasting-mimicking diet is effective in reducing total cholesterol levels.
- Trial name
- NCT06610565
- Testing
- FASTING-MIMICKING DIET PROGRAM
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Breast Cancer
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
This is a single-centre study comprising two phases: a lead-in phase Ib and a phase II randomized portion. Lead-in Phase Ib study A lead-in phase I study will be built into this protocol to confirm the dose of lenvatinib that can…
- Trial name
- NCT02562118
- Testing
- Lenvatinib + Letrozole
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National University Hospital, Singapore
Estrogen Receptor Positive Breast Cancer
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
Some breast cancers have estrogen receptors (ER+). The investigators know that some ER+ tumours can be cured by hormone therapy alone while other ER+ breast cancers cannot.
- Trial name
- PRESTO (NCT02238808)
- Testing
- Estradiol
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
Patients with estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) breast cancer do not achieve good responses with pre-operative chemotherapy.
- Trial name
- NCT05069038
- Testing
- Palbociclib 125mg
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Nebraska
Breast Cancer
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-)…
- Trial name
- NCT06139107
- Testing
- Abemaciclib, Letrozole
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Mridula George, MD
Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom.
- Trial name
- NCT06450873
- Testing
- Coriolus Versicolor Extract, Questionnaire Administration
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Hormone Receptor Positive Early Breast Cancer
A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole…
- Trial name
- SIE-1 (NCT07401381)
- Testing
- US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE
- Where
- 21 sites in United States, Serbia and 1 more
- Volunteers
- 120 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Breast Cancer
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
The purpose of the study is to to compare low dose of exemestane (babyexe) versus low dose of tamoxifen (babytam) in terms of change of quality of life from baseline to 12 months.
- Trial name
- BabyTears (NCT06364267)
- Testing
- Tamoxifen 10 MG, Exemestane 25 MG
- Where
- Italy
- Volunteers
- 140 people
- Sponsor
- Andrea DeCensi